Hypogonadism in thalassemia major patients
- PMID: 29067234
- PMCID: PMC5644428
- DOI: 10.1016/j.jcte.2016.08.001
Hypogonadism in thalassemia major patients
Abstract
Despite recent advances in iron chelation therapy, excess iron deposition in pituitary gonadotropic cells remains one of the major problems in thalassemic patients. Hypogonadism, mostly hypogonadotropic hypogonadism, is usually detected during puberty. Early diagnosis and treatment are crucial for normal pubertal development and to reduce the complications of hypogonadism. The risks and benefits of hormonal replacement therapy, especially regarding the thromboembolic event, remain a challenge for providers caring for thalassemic patients.
Keywords: Hypogonadism; Thalassemia.
References
-
- Weatherall D.J. Disorder of globin synthesis: the thalassemias. In: Lichtman M.A., Beutler E., Kipps T.J., Seligsohn U., Kaushansky K., Prchal J.T., editors. Williams hematology. 7th ed. McGraw-Hill; New York: 2006. pp. 633–666.
-
- Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci. 2010;1202:1–9. - PubMed
-
- Jameson J.L., Groot L.J.D. 7th ed. Elsevier; Philadelphia: 2016. Endocrinology: adult and pediatric.
-
- Atkin S.L., Hipkin L.J., Landolt A.M., Jeffreys R.V., Foy P.M., White M.C. Effect of cell density on hormonal secretion from human pituitary adenomas in vitro. Horm Res. 1998;49(5):203–209. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources